NCT00944554

Relapse Prevention With Varenicline

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

Detailed description

In this study, the investigators plan to use an experimental model of a lapse, in which volunteers smoke two cigarettes after a brief period of (12-24 hours). The goals of this study are to assess the impact of varenicline on the subjective and reinforcing effects of cigarettes, as well as the latency to resume smoking (relapse) following the lapse exposure.

Conditions

• Recurrence
• Smoking Cessation
• Substance-Related Disorders

Interventions

Type	Name	Description
DRUG	Varenicline	Varenicline given twice a day or five weeks.
DRUG	Placebo	Placebo given twice a day or five weeks.

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2009-07-23
• Last updated: 2017-08-03
• Results posted: 2017-06-23

Locations

1 site across 1 country: United States